The COVID-19 war and the battles of rheumatologists

Abstract

Not available

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

References

Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China [published online ahead of print, 2020 Feb 28]. N Engl J Med. 2020;10.1056/NEJMoa2002032. doi:10.1056/NEJMoa2002032 DOI: https://doi.org/10.1056/NEJMoa2002032

Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. doi:10.1056/NEJMoa2001017 DOI: https://doi.org/10.1056/NEJMoa2001017

Henry BM, Vikse J. Clinical Characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1860‐1861. doi:10.1056/NEJMc2005203 DOI: https://doi.org/10.1056/NEJMc2005203

Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787‐1799. doi:10.1056/NEJMoa2001282 DOI: https://doi.org/10.1056/NEJMoa2001282

Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020;382(24):2327‐2336. doi:10.1056/NEJMoa2007016 DOI: https://doi.org/10.1056/NEJMoa2007016

Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? [published online ahead of print, 2020 Mar 22]. Clin Exp Rheumatol. 2020

Birra D, Benucci M, Landolfi L, et al. COVID 19: a clue from innate immunity [published online ahead of print, 2020 Jun 10]. Immunol Res. 2020;10.1007/s12026-020-09137-5. doi:10.1007/s12026-020-09137-5 DOI: https://doi.org/10.1007/s12026-020-09137-5

Benucci M, Damiani A, Infantino M, Manfredi M, Quartuccio L. Old and new antirheumatic drugs for the treatment of COVID-19. Joint Bone Spine. 2020;87(3):195‐197. doi:10.1016/j.jbspin.2020.03.013 DOI: https://doi.org/10.1016/j.jbspin.2020.03.013

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;92(7):814‐818. doi:10.1002/jmv.25801 DOI: https://doi.org/10.1002/jmv.25801

Aouba A, Baldolli A, Geffray L, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series [published online ahead of print, 2020 May 6]. Ann Rheum Dis. 2020;annrheumdis-2020-217706. doi:10.1136/annrheumdis-2020-217706 DOI: https://doi.org/10.1136/annrheumdis-2020-217706

Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305-306. doi:10.1038/d41573-020-00073-5 DOI: https://doi.org/10.1038/d41573-020-00073-5

Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-2765. doi:10.1172/JCI138745 DOI: https://doi.org/10.1172/JCI138745

Raoult D, Hsueh PR, Stefani S, Rolain JM. COVID-19 Therapeutic and Prevention. Int J Antimicrob Agents. 2020;55(4):105937. doi:10.1016/j.ijantimicag.2020.105937 DOI: https://doi.org/10.1016/j.ijantimicag.2020.105937

Sciascia S, Aprà F, Baffa A, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020;38(3):529-532.

Tu F, Chien CS, Yarmishyn AA, et al. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 2020;21(7):2657. Published 2020 Apr 10. doi:10.3390/ijms21072657 DOI: https://doi.org/10.3390/ijms21072657

Gupta N, Agrawal S, Ish P. Chloroquine in COVID-19: the evidence. Monaldi Arch Chest Dis. 2020; 90(1): 10.4081/monaldi.2020.1290. DOI: https://doi.org/10.4081/monaldi.2020.1290

Yazdany J, Kim AHJ. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020;172(11):754-755. doi:10.7326/M20-1334 DOI: https://doi.org/10.7326/M20-1334

https://www.aifa.gov.it/-/covid-19-studio-randomizzato-italiano-nessun-beneficio-dal-tocilizumab

Quartuccio L, Sonaglia A, McGonagle D, et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care [published online ahead of print, 2020 May 15]. J Clin Virol. 2020;129:104444. doi:10.1016/j.jcv.2020.104444 DOI: https://doi.org/10.1016/j.jcv.2020.104444

Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851-858. doi:10.1136/annrheumdis-2020-217877 DOI: https://doi.org/10.1136/annrheumdis-2020-217877

Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic. Arthritis Rheumatol. 2020;10.1002/art.41301. doi:10.1002/art.41301 DOI: https://doi.org/10.1002/art.41301

Sarzi-Puttini P, Marotto D, Antivalle M, et al. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmun Rev. 2020;19(7):102574. doi:10.1016/j.autrev.2020.102574 DOI: https://doi.org/10.1016/j.autrev.2020.102574

Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679‐1681. doi:10.1056/NEJMp2003539 DOI: https://doi.org/10.1056/NEJMp2003539

Portnoy J, Waller M, Elliott T. Telemedicine in the Era of COVID-19. J Allergy Clin Immunol Pract. 2020;8(5):1489‐1491. doi:10.1016/j.jaip.2020.03.008 DOI: https://doi.org/10.1016/j.jaip.2020.03.008

Bashshur R, Doarn CR, Frenk JM, Kvedar JC, Woolliscroft JO. Telemedicine and the COVID-19 Pandemic, Lessons for the Future. Telemed J E Health. 2020;26(5):571‐573. doi:10.1089/tmj.2020.29040.rb DOI: https://doi.org/10.1089/tmj.2020.29040.rb

Perniola S, Alivernini S, Varriano V, et al. Telemedicine will not keep us apart in COVID-19 pandemic. Ann Rheum Dis. 2020;annrheumdis-2020-218022. doi:10.1136/annrheumdis-2020-218022 DOI: https://doi.org/10.1136/annrheumdis-2020-218022

Published
2020-09-08
Info
Issue
Section
Editorials
Keywords:
COVID-19, rheumatologists, editorial.
Statistics
  • Abstract views: 685

  • PDF: 158
  • HTML: 0
How to Cite
Migliore, A., & Birra, D. (2020). The COVID-19 war and the battles of rheumatologists. Beyond Rheumatology, 2(2), 41-42. https://doi.org/10.4081/br.2020.43